Hemispherx Videos

Hemispherx News

Hemispherx Biopharma (NYSE:HEB) Initiated at Maxim with Buy and $8 Target

Maxim analyst Jason McCarthy initiated Hemispherx with a Buy rating and a price target of $8, citing the company's "differentiated immune oncology approach". Ampligen leverages...

Hemispherx Biopharma Announces Significant Progress in its Ampligen Ovarian Cancer Program

OCALA, Fla., April 30, 2019 (GLOBE NEWSWIRE) -- (NYSE American: HEB) — Hemispherx Biopharma Inc., an immuno-pharma company focused on the research and development...

Hemispherx Articles

Hemispherx Bio up 22% on Ampligen + Keytruda studies: SeekingAlpha

Thinly traded nano cap Hemispherx Biopharma (HEB +22.1%) is up on a 7x surge in volume in reaction to its announcement of two clinical...